Literature DB >> 12612962

Vascular calcification in dialysis patients: pathogenesis and consequences.

Martina Reslerova1, Sharon M Moe.   

Abstract

BACKGROUND: Vascular calcification is believed to have a crucial role in the excess cardiovascular mortality and morbidity in patients with end-stage renal disease (ESRD). METHODS AND
RESULTS: Recent evidence suggests that uremic vascular calcification is an active cell-mediated process resembling osteogenesis in bone, rather than passive precipitation of calcium and phosphorus in the setting of deranged mineral metabolism. To date, several bone-associated proteins (osteopontin, bone sialoprotein, alkaline phosphatase, and type I collagen) have been shown in histological sections of vessels obtained from patients with ESRD or calcific uremic arteriolopathy. In in vitro experiments, the addition of uremic serum upregulates osteopontin expression by cultured vascular smooth muscle cells (VSMCs).
CONCLUSION: We are only beginning to understand the process by which VSMCs transform into osteoblast-like cells, although phosphorus may have a key role. Additional factors mediating or modulating the development of vascular calcification in patients with ESRD remain to be identified. Further understanding of the pathophysiological state of uremic vascular calcification is needed to design effective therapeutic strategies to intervene with this devastating condition in the ESRD population.

Entities:  

Mesh:

Year:  2003        PMID: 12612962     DOI: 10.1053/ajkd.2003.50094

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  20 in total

Review 1.  Calciphylaxis and vascular calcification: a continuum of extra-skeletal osteogenesis.

Authors:  Sharon M Moe; Neal X Chen
Journal:  Pediatr Nephrol       Date:  2003-10       Impact factor: 3.714

2.  Phosphate binders in dialyzed patients: efficacy and cost.

Authors:  José Ignacio Minguela; Ramón Ruiz-De-Gauna
Journal:  Pediatr Nephrol       Date:  2004-06-16       Impact factor: 3.714

3.  Primary bypass surgery from the descending aorta to the iliac arteries for a severely calcified aorta: report of two cases.

Authors:  Osamu Sato; Hiroyuki Okamoto; Harunobu Matsumoto; Kouji Ogata; Keisuke Kondoh
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

4.  Severe vascular calcification and gangrene in a haemodialysis patient.

Authors:  Mohammed Mahdi Althaf; Mohamed Said Abdelsalam; Quaid Nadri
Journal:  BMJ Case Rep       Date:  2014-02-21

5.  Calciphylaxis in pediatric end-stage renal disease.

Authors:  Abubakr A Imam; Tej K Mattoo; Gaurav Kapur; David A Bloom; Rudolph P Valentini
Journal:  Pediatr Nephrol       Date:  2005-08-25       Impact factor: 3.714

6.  Comparative mortality-predictability using alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and hemodialysis.

Authors:  Connie M Rhee; Miklos Z Molnar; Wei Ling Lau; Vanessa Ravel; Csaba P Kovesdy; Rajnish Mehrotra; Kamyar Kalantar-Zadeh
Journal:  Perit Dial Int       Date:  2014-01-02       Impact factor: 1.756

7.  Large artery calcification on dialysis patients is located in the intima and related to atherosclerosis.

Authors:  Blai Coll; Angels Betriu; Montserrat Martínez-Alonso; Maria Luisa Amoedo; Maria Vittoria Arcidiacono; Merce Borras; Jose Manuel Valdivielso; Elvira Fernández
Journal:  Clin J Am Soc Nephrol       Date:  2010-10-07       Impact factor: 8.237

8.  The roles of the skeleton and phosphorus in the CKD mineral bone disorder.

Authors:  Keith A Hruska; Suresh Mathew
Journal:  Adv Chronic Kidney Dis       Date:  2011-03       Impact factor: 3.620

9.  Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients.

Authors:  Deborah L Regidor; Csaba P Kovesdy; Rajnish Mehrotra; Mehdi Rambod; Jennie Jing; Charles J McAllister; David Van Wyck; Joel D Kopple; Kamyar Kalantar-Zadeh
Journal:  J Am Soc Nephrol       Date:  2008-07-30       Impact factor: 10.121

Review 10.  [Atherosclerosis and uremia: signifance of non-traditional risk factors].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2003-04-30       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.